SLXN

Insider Trades

Name	Value	Action	Price	Current Price
Shirvan MitchellCSO And CDO $31k22.8k shares SellMar 26, 2026 $1.36 --

News

globenewswire.comSilexion Therapeutics to Attend BIO International Convention 2026globenewswire.comJun 16

globenewswire.comSilexion Therapeutics Announces 1-for-10 Reverse Share Splitglobenewswire.comMay 26

globenewswire.comSilexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updateglobenewswire.comMay 18

globenewswire.comSilexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceedsglobenewswire.comMay 15

globenewswire.comSilexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancerglobenewswire.comMay 14

Trade SLXN

About Silexion Therapeutics Ltd.

Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.

CEO: Ilan Hadar
IPO Date: Aug 16, 2024

Market Data

Open: $2.75
High: $2.91
Low: $2.65
Volume: 67.8K
Avg Volume: 614.2K
52W High: $223.60
52W Low: $2.31

Valuation

Market Cap: $1.1M
Enterprise Value: $-833k
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-11M
Revenue: $0
Net Income: $-12M
Cash: $6.0M
Debt: $468k

Events

EarningsAug 11

EPS est. -13.1